Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer [Phase 3]
A Phase 3 clinical trial comparing SYSA1901 to Perjeta in HER2-positive breast cancer is underway, with the status currently unknown.
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial evaluating whether local treatments (surgery or high-dose radiation) to metastatic sites in breast cancer i…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer [Phase 2]
Phase II trial of Doxil (liposomal doxorubicin), carboplatin, and bevacizumab in untreated metastatic breast cancer has completed with resul…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer [Phase 2]
Phase 2 trial evaluating prevention of cardiovascular diseases in women with breast cancer undergoing complex treatment; completed.
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD [Phase 2]
A Phase 2 trial of tucatinib, trastuzumab, and capecitabine for HER2-positive leptomeningeal disease in metastatic breast cancer was termina…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-02-03Clinical Trial Update: Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel [Phase 2, Phase 3]
Clinical trial update for Balugrastim (Neugranin) in breast cancer patients receiving doxorubicin/docetaxel; Phase 2/3 completed with result…
-
CLINICAL_TRIALS trial_result · 2023-02-02Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) [Phase 2]
Phase 2 trial comparing giredestrant plus palbociclib to anastrozole plus palbociclib in untreated postmenopausal ER-positive, HER2-negative…
-
CLINICAL_TRIALS trial_result · 2023-02-02Clinical Trial Update: Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer [NA]
Clinical trial comparing early surgery versus standard palliative therapy in patients with stage IV breast cancer has completed; results pos…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer [Phase 2]
A Phase 2 neoadjuvant trial in breast cancer, including triple-negative cases, evaluated carboplatin/paclitaxel followed by doxorubicin/cycl…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: Breast Cup Immobilization Device II (GCC 1047)
A completed clinical trial involves a Breast Cup Immobilization Device (GCC 1047) for breast cancer; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA) [Phase 2]
Phase 2 trial of pembrolizumab plus carboplatin in metastatic breast cancer (PEMBRACA) has completed.
-
FDA approval · 2023-01-27FDA Approved: ORSERDU — Original Application (Stemline Therapeutics, Inc.)
FDA approved ORSERDU (elacestrant) for ER-positive, HER2-negative advanced or metastatic breast cancer following aromatase inhibitor therapy…
-
CLINICAL_TRIALS trial_result · 2023-01-26Clinical Trial Update: MRI-Based Preoperative Accelerated Partial Breast Irradiation [NA]
Clinical trial update for MRI-based preoperative accelerated partial breast irradiation in breast cancer, with results posted in January 202…
-
CLINICAL_TRIALS trial_result · 2023-01-26Clinical Trial Update: Thero2-01S22 in HER2-positive Breast Cancer [Phase 3]
Phase 3 trial update for Thero2-01S22 in HER2-positive breast cancer (not yet recruiting).
-
CLINICAL_TRIALS trial_result · 2023-01-26Clinical Trial Update: A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer [Phase 1, Phase 2]
A dose-escalation study evaluating the combination of Trastuzumab Emtansine (T-DM1) with Neratinib in women with metastatic HER2-positive br…
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery [Phase 2]
Phase 2 clinical trial of talimogene laherparepvec for recurrent breast cancer that cannot be removed surgically has been terminated; result…
-
CLINICAL_TRIALS trial_result · 2023-01-23Clinical Trial Update: Contrast Ultrasound Detection of Sentinel Lymph Nodes [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating contrast-enhanced ultrasound for detection of sentinel lymph nodes in breast cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer [Phase 3]
Phase 3 trial comparing EG12014 to Herceptin in HER2-positive early breast cancer completed.
-
FDA approval · 2023-01-19FDA Approved: TUKYSA — Supplemental Application (SEAGEN INC.)
FDA approved a supplemental application for TUKYSA (tucatinib) from Seagen, resulting in an updated label/indication for the drug.
-
CLINICAL_TRIALS trial_result · 2023-01-19Clinical Trial Update: Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line [Phase 3]
A Phase 3 trial assessing ribociclib with endocrine therapy or chemotherapy, with or without bevacizumab, as first-line treatment for metast…
-
CLINICAL_TRIALS trial_result · 2023-01-19Clinical Trial Update: Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer [Phase 1, Phase 2]
Phase 1/2 trial of an anti-PD-1 antibody with radiation therapy in HER2-negative metastatic breast cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-18Clinical Trial Update: Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases [Phase 1, Phase 2]
A clinical trial evaluating pyrotinib combined with brain radiotherapy for patients with breast cancer and brain metastases (Phase 1/2).
-
CLINICAL_TRIALS trial_result · 2023-01-17Clinical Trial Update: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. [Phase 3]
Phase 3 trial update evaluating olaparib monotherapy for metastatic breast cancer focused on HER2-negative disease with germline BRCA1/2 mut…
-
CLINICAL_TRIALS trial_result · 2023-01-17Clinical Trial Update: Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women [Phase 3]
Phase 3 trial update on adjuvant ovarian suppression plus aromatase inhibitor or tamoxifen in young women with breast cancer.
-
CLINICAL_TRIALS trial_result · 2023-01-13Clinical Trial Update: Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating a multi-epitope folate receptor alpha peptide vaccine with GM-CSF and cyclophosphamide for treating triple…